According to preliminary data provided by the Haifa-based company, not only have all six of the critically ill coronavirus patients that were treated survived, but four of them showed improvement in respiratory parameters.
Six critically ill coronavirus patients in Israel who are considered high-risk for mortality have been treated with Pluristem’s placenta-based cell-therapy product and survived, according to preliminary data provided by the Haifa-based company.
The patients were treated at three different Israeli medical centers for one week under the country’s compassionate use program and were suffering from acute respiratory failure and inflammatory complications associated with COVID-19. Continue Reading »
Israeli New Shekel Exchange Rate